FindTrial
Sign In

csDMARDs

DRUG4 trials

Sponsors

Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, The First Affiliated Hospital of Xiamen University

Conditions

Arthritis, RheumatoidRheumatoid Arthritis

Phase 3

A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy
CompletedNCT02001987
Hoffmann-La RocheRheumatoid Arthritis
Start: 2014-01-31End: 2015-12-31Updated: 2018-11-02
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
CompletedNCT02873936
Gilead SciencesRheumatoid Arthritis
Start: 2016-07-27End: 2018-06-26Updated: 2021-05-13
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors
CompletedNCT04134728
GlaxoSmithKlineArthritis, Rheumatoid
Start: 2019-10-31End: 2022-02-01Updated: 2023-07-17

Unknown Phase

Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients
NCT05424393
The First Affiliated Hospital of Xiamen UniversityRheumatoid Arthritis
Start: 2022-03-04End: 2025-12-31Target: 500Updated: 2022-06-21

Related Papers

Integrated Safety Analysis of Filgotinib in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis Over a Treatment Duration of up to 5 Years.
2026-03-17
OA12 An update on the integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis over a median of 4.3 years
Lara D. Veeken2025-04-01
Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4
Modern Rheumatology2024-11-07
Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study
RMD Open2024-10-013 citations
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years.
2024-08-279 citations
Patients with High Baseline Neutrophil-to-Lymphocyte Ratio Exhibit Better Response to Filgotinib as Treatment for Rheumatoid Arthritis.
2024-07-10
P117 Efficacy of filgotinib in patients with rheumatoid arthritis: Week 156 results from a long-term extension study
Lara D. Veeken2024-04-01
P112 The Impact of Filgotinib on Disease Activity Outcomes With Concomitant Pain Control in the Phase 3 FINCH Studies
Lara D. Veeken2024-04-01
Impact of filgotinib on pain control in the phase 3 FINCH studies
RMD Open2024-03-017 citations
Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis.
2023-12-062 citations
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis.
2023-09-257 citations
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
2023-09-1116 citations
AB0290 EFFECT OF FILGOTINIB ON PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE PHASE 3 FINCH 1, 2 AND 3 STUDIES
2023-05-301 citations
OA06 Clinical outcomes of filgotinib in patients with rheumatoid arthritis aged ≥65 years: a post hoc subgroup analysis of Phase 2 and 3 clinical trials and ongoing long-term extensions
Lara D. Veeken2023-04-011 citations
P111 Exploratory Analysis of Filgotinib Safety Data in Patients With Moderately to Severely Active Rheumatoid arthritis and an Increased Risk of Cardiovascular Events: Data From Phase 2 and 3 Clinical Trials
Lara D. Veeken2023-04-01
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)
European Respiratory Journal2022-10-1342 citations
Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis.
2022-10-071 citations
P199 Clinical outcomes up to week 48 of ongoing filgotinib rheumatoid arthritis long-term extension trial of biologic disease modifying anti-rheumatic drugs inadequate responders initially on filgotinib or placebo in a Phase 3 trial
Lara D. Veeken2022-04-23
P204 Filgotinib demonstrates clinical efficacy in rheumatoid arthritis independent of smoking status: a post-hoc subgroup analysis of three Phase 3 clinical trials
Lara D. Veeken2022-04-23
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years
Modern Rheumatology2022-04-024 citations

11 more papers not shown